+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

ASD Closure in Structural Heart Disease

ASD Closure in Structural Heart Disease

Current Cardiology Reports 20(6): 37-37

While the safety and efficacy of percutaneous ASD closure has been established, new data have recently emerged regarding the negative impact of residual iatrogenic ASD (iASD) following left heart structural interventions. Additionally, new devices with potential advantages have recently been studied. We will review here the potential indications for closure of iASD along with new generation closure devices and potential late complications requiring long-term follow-up. With the expansion of left-heart structural interventions and large-bore transseptal access, there has been growing experience gained with management of residual iASD. Some recently published reports have implicated residual iASD after these procedures as a potential source of diminished clinical outcomes and mortality. Additionally, recent trials investigating new generation closure devices as well as expanding knowledge regarding late complications of percutaneous ASD closure have been published. While percutaneous ASD closure is no longer a novel approach to managing septal defects, there are several contemporary issues related to residual iASD following large-bore transseptal access and new generation devices which serve as an impetus for this review. Ongoing attention to potential late complications and decreasing their incidence with ongoing study is clearly needed.

(PDF emailed within 0-6 h: $19.90)

Accession: 050028977

Download citation: RISBibTeXText

PMID: 29666940

DOI: 10.1007/s11886-018-0983-x

Related references

The SCAI Structural Heart Disease Council: toward addressing training, credentialing, and guidelines for structural heart disease intervention. Catheterization and Cardiovascular Interventions 76(4): E87-E89, 2011

TCTAP A-054 VSD Transcatheter Closure Is an Accepted Mode of Treatment in Selected Cases of Congenital Heart Disease. Lately, This Technology Has Been Applied to Closure of Ventricular Septal Defect (VSD). Journal of the American College of Cardiology 65(17): S29-S30, 2015

Valvular and congenital heart disease - Left ventricular remodeling and change of systolic function after closure of patent ductus arteriosus in adults: Device and surgical closure. American Heart Journal 154(3): 436-440, 2007

Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation 91(5): 1596-1601, 1995

Treating a Structural Heart Disease Using a Non-structural Approach: Role of Cardiac Pacing in Hypertrophic Cardiomyopathy. Cardiology Research 8(1): 20-25, 2017

New-onset heart failure in children in the absence of structural congenital heart disease. Circulation 117(1): 11-12, 2008

Heart Failure Interventions Targeting Impaired Left Ventricles in Structural Heart Disease. Current Cardiology Reports 20(2): 8-8, 2018

Exercise cardiac magnetic resonance to differentiate athlete's heart from structural heart disease. European Heart Journal Cardiovascular Imaging, 2018

Mitral and tricuspid valve closure in congenital heart disease. Circulation 53(3): 513-518, 1976

Early closure of the sternal sutures and congenital heart disease. American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine 89: 975-983, 1963

VSD closure device in the setting of adult congenital heart disease. Catheterization and Cardiovascular Interventions 64(2): 213-213, 2005

Delayed closure of the aortic valve in ischaemlc heart disease. Brit Heart J 29(5): 775-777, 1967

Heart rate turbulence after ventricular and atrial premature beats in subjects without structural heart disease. Journal of Cardiovascular Electrophysiology 14(5): 447-452, 2003

Correction for heart rate is not necessary for QT dispersion in individuals without structural heart disease and patients with ventricular tachycardia. Annals of Noninvasive Electrocardiology 7(1): 47-52, 2002

The structural bases of heart failure in ischemic heart disease. Vrachebnoe Delo: 22-24, 1990